Boehringer Ingelheim withheld safety analyses on new anticoagulant (Dabigatran shenanigans)

[sakigt]

Discuss

http://www.bmj.com/content/349/bmj.g4756

http://www.bmj.com/content/349/bmj.g4670

http://www.bmj.com/content/349/bmj.g4747

http://www.bmj.com/content/349/bmj.g4681

---

Members don't see this ad.

 

[tungsten87]

not a fan of the new oral anticoagulants - they all have their own limitations. edoxaban, however, looks very promising.

 

[fewaopi]

isn't this the kind of stuff Ben Goldacre talks about? it's not much of a surprise then is it? if anything it's probably the norm in industry, playing with numbers, holding back trial data, etc.